Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 6/20 | 0.54 |
| ▸ | TFPI | P10646 | 1/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.50 |
| ▸ | FURIN | P09958 | 1/20 | 0.50 |
| ▸ | GLP1R | P43220 | 2/20 | 0.49 |
| ▸ | GCGR | P47871 | 1/20 | 0.49 |
| ▸ | GIPR | P48546 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.48 |
| ▸ | NPY1R | P25929 | 2/20 | 0.48 |
| ▸ | NPY4R | P50391 | 2/20 | 0.48 |
| ▸ | NMT2 | O60551 | 1/20 | 0.47 |
| ▸ | NMT1 | P30419 | 1/20 | 0.47 |
| ▸ | ECE1 | P42892 | 1/20 | 0.47 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13363672 | 0.95 | RXFP1 (0.54) | RXFP1TFPIPRSS1FURINGLP1R | |
| SCHEMBL16507926 | 0.94 | NPY4R (0.53) | RXFP1PRSS1FURINGLP1RGCGR | |
| SCHEMBL16507959 | 0.92 | RXFP1 (0.59) | RXFP1TFPIGLP1RGCGRGIPR | |
| SCHEMBL16508129 | 0.88 | NPY4R (0.52) | RXFP1PRSS1FURINGLP1RGCGR | |
| SCHEMBL16508088 | 0.85 | NPY4R (0.51) | RXFP1TFPIPRSS1FURINGLP1R | |
| SCHEMBL16507762 | 0.85 | TFPI (0.56) | RXFP1TFPIGLP1RGCGRGIPR | |
| SCHEMBL16507937 | 0.84 | RXFP1 (0.55) | RXFP1TFPIGLP1RGCGRGIPR | |
| SCHEMBL16507855 | 0.84 | RXFP1 (0.55) | RXFP1TFPIGLP1RGCGRGIPR | |
| SCHEMBL16976058 | 0.84 | NPY4R (0.60) | RXFP1TLR2NPY5RNPY1RNPY4R | |
| SCHEMBL15186049 | 0.84 | ECE1 (0.60) | GLP1RECE1MUS81 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | ANTHOR THERAPEUTICS, INC. | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294738-A1 | PTHR1 RECEPTOR COMPOUNDS | PTH1R, MC1R, CASR | RXFP1 568/4885TFPI 2646/4885PRSS1 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.